For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $6.95 in the last session, down -0.43% from day before closing price of $6.98. In other words, the price has decreased by -$0.43 from its previous closing price. On the day, 9.81 million shares were traded. RXRX stock price reached its highest trading level at $7.14 during the session, while it also had its lowest trading level at $6.75.
Ratios:
We take a closer look at RXRX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.35 and its Current Ratio is at 4.35. In the meantime, Its Debt-to-Equity ratio is 0.17 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 11 ’24 when Secora Michael bought 15,000 shares for $7.48 per share.
Secora Michael bought 15,000 shares of RXRX for $116,324 on Dec 10 ’24. On Dec 04 ’24, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 20,000 shares for $7.16 each. As a result, the insider received 143,200 and left with 736,633 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2703132928 and an Enterprise Value of 1656503680. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.28 while its Price-to-Book (P/B) ratio in mrq is 3.79. Its current Enterprise Value per Revenue stands at 25.413 whereas that against EBITDA is -4.549.
Stock Price History:
Over the past 52 weeks, RXRX has reached a high of $15.74, while it has fallen to a 52-week low of $5.60. The 50-Day Moving Average of the stock is 3.35%, while the 200-Day Moving Average is calculated to be -12.18%.
Shares Statistics:
According to the various share statistics, RXRX traded on average about 8.08M shares per day over the past 3-months and 17279240 shares per day over the past 10 days. A total of 388.78M shares are outstanding, with a floating share count of 322.67M. Insiders hold about 17.01% of the company’s shares, while institutions hold 58.14% stake in the company. Shares short for RXRX as of 1732838400 were 67845763 with a Short Ratio of 8.40, compared to 1730332800 on 62427631. Therefore, it implies a Short% of Shares Outstanding of 67845763 and a Short% of Float of 19.03.
